Testosterone gender affirming hormone therapy (T-GAHT) is frequently used by transgender
and gender-diverse individuals assigned female at birth to establish masculinizing …

BACKGROUND Transgender and gender diverse (TGD) people seek gender-affirming care
at any age to manage gender identities or expressions that differ from their birth gender …

In brief Animal studies are needed to inform clinical guidance on the effects of testosterone
gender-affirming hormone therapy (T-GAHT) on fertility. This review summarizes current …

Background: Exposure to obesogenic chemicals has been reported to result in enhanced
adipogenesis, higher adipose tissue accumulation, and reduced ovarian hormonal …

Ovarian function is controlled by pituitary secretion of luteinizing hormone (LH) and follicle
stimulating hormone (FSH), which in turn are governed by gonadotropin releasing hormone …

In brief Transgender, non-binary and gender-diverse patients utilizing feminizing gender-
affirming hormone therapy (GAHT) may experience reduced fertility, which is currently …

It is estimated that over 1.6 million adults and adolescents identify as transgender or gender
diverse in the United States, representing 0.6% of the population. 1 Extrapolating similar …

Gender-affirming hormone therapy (GAHT) is an important component in the process of
transitioning for many transgender and gender-diverse (TGD) individuals. Multiple medical …

Fertility preservation (FP) involves the cryopreservation of gametes, embryos, and/or
gonadal tissue oocytes, for future use in family building. FP as part of a comprehensive …

Modern families are created in various ways, and the “traditional family” consisting of a
cisgender heterosexual couple in their first marriage with biological children is just 1 family …